CNS Pharmaceuticals ( (CNSP) ) has provided an update.
CNS Pharmaceuticals has completed enrollment in a pivotal clinical trial for Berubicin, a promising treatment for glioblastoma multiforme, with primary data analysis expected in the first half of 2025. The company has also in-licensed TPI 287, which has received Orphan and Fast Track designations, indicating strong potential for addressing unmet needs in brain cancer treatment.
More about CNS Pharmaceuticals
CNS Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel treatments for brain cancer. Its lead program involves Berubicin, a novel anthracycline for glioblastoma multiforme, a type of brain cancer, and it has expanded its pipeline with TPI 287, a taxane derivative for brain malignancies.
YTD Price Performance: -3.33%
Average Trading Volume: 16,953,859
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $6.72M
See more insights into CNSP stock on TipRanks’ Stock Analysis page.